Author + information
- Received December 3, 1991
- Revision received February 20, 1992
- Accepted March 20, 1992
- Published online October 1, 1992.
- ↵∗Address for correspondence: Thomas Paul, MD, Pediatric Cardiology, Hannover Medical School, PO Box 610180, D-3000 Hannover 61, Germany.
Objectives. Class 1C anliarrhythmic drugs have recently been shown to be effective in some patients with atrial ectopic tachycardia. We therefore studied the efficacy of these drugs in patients with congenital junctional ectopic tachycardia.
Background. Follow-up data on patients with Junctional eclopic tachycardia suggest that this potentially lethal arrhythmia may cease spontaneously in a significant proportion af affected children. Therefore, temporary antiarrhythmic treatment appears to be the therapy of choice.
Methods. The efficacy of propafenone was prospectively assessed in four infants with Junctional ectopic tachycardia (ventricular rate 180, 185, 210 and 320 beats/min, respectively). The diagnosis of Junctional ectopic tachycardia was established before the age of 2 months in all four infants. Propafenone was given orally in a mean dose of 350 (300 to 500) mg/m2body surface area per day. Success of therapy was determised by serial electrocardiograms (ECGs) and Holler ambulatory ECG monitoring.
Results. In two patients, junctional ectopic tachycardia was completely suppressed. In the remaining two patients, the tachycardia rate decreased to < 150 beats/min. Serum propafenone levels did not correlate with efficacy of treatment. The mean duration of therapy was 18 months (range 3 to 36). No chemical or clinical side effects were noted.
Conclusions. Because of its effectiveness, safety and lack of side effects, propafenone appears to be a valuable drug in the treatment of Junctional ectopic tachycardia in newborns and infants.
- Received December 3, 1991.
- Revision received February 20, 1992.
- Accepted March 20, 1992.
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.